Advertisement If and when semaglutide and other GLP-1 receptor agonists are widely used for cardiovascular prevention in patients with overweight and obesity without diabetes, cardiologists will need to gain familiarity with their use
At a glance Issue 30% of people living in Canada have diabetes or prediabetes meaning their blood sugar is too high
There was no difference in the risk of CV death when GLP-1RA were compared with SGLT-2 inhibitors
For example, hypervitaminosis A can be caused by taking one large dose of over 200 mg of vitamin A, or chronic use of more than 10 times the recommended daily intake ( Vitamin A toxicity may lead to serious complications, such as increased spinal fluid pressure, coma, and potentially fatal organ damage ( Additionally, taking megadoses of vitamin D more than 50,000 IU daily over long periods can lead to high blood levels of calcium (hypercalcemia), which can lead to death ( Overdosing on other vitamins can likewise cause potentially fatal side effects, such as liver damage
I think this is truly amazing work
H ow may GIP enhance the therapeutic efficacy of GLP-1